AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
243.35B
Market cap243.35B
Price-Earnings ratio
23.22
Price-Earnings ratio23.22
Dividend yield
2.00%
Dividend yield2.00%
Average volume
4.25M
Average volume4.25M
High today
$157.29
High today$157.29
Low today
$157.20
Low today$157.20
Open price
$156.22
Open price$156.22
Volume
16.76K
Volume16.76K
52 Week high
$212.71
52 Week high$212.71
52 Week low
$145.79
52 Week low$145.79

Stock Snapshot

As of today, AstraZeneca(AZN) shares are valued at $157.28. The company's market cap stands at 243.35B, with a P/E ratio of 23.22 and a dividend yield of 2.00%.

On 2026-08-18, AstraZeneca(AZN) stock moved within a range of $157.20 to $157.29. With shares now at $157.28, the stock is trading +0.1% above its intraday low and -0.0% below the session's peak.

Trading activity shows a volume of 16.76K, compared to an average daily volume of 4.25M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

AZN News

Simply Wall St 17h
AstraZeneca Stock Tops 3 Cash Flow Bargains Worth A Closer Look - simplywall.st

...

AstraZeneca Stock Tops 3 Cash Flow Bargains Worth A Closer Look - simplywall.st
TipRanks 22h
AstraZeneca to discontinue eVOLVE-Lung02 Phase III trial

AstraZeneca (AZN) announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line the...

TipRanks 1d
AstraZeneca announces results from Phase III trial of Tagrisso, savolitinib

Positive high-level results from the Saffron Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful...

Analyst ratings

87%

of 30 ratings
Buy
86.7%
Hold
10%
Sell
3.3%

More AZN News

TipRanks 1d
AstraZeneca: Volrustomig Setback Offset by Oncology Pipeline Strength; Buy Rating and 16,500 GBp Price Target Maintained

In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca, with a price target of p16,500.00. Unlock power...

TipRanks 1d
AstraZeneca’s Enhertu tops standard care in first-line HER2-mutant lung cancer trial

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Nasdaq 3d
Are Mega-Mergers Back?

In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: AstraZeneca + BMS? Why m...

Are Mega-Mergers Back?
Nasdaq 4d
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if o...

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
TipRanks 5d
AstraZeneca’s STEP Asthma Trial Completion: What It Could Mean for AZN Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident...

TipRanks 6d
AstraZeneca Targets Indian Lung Cancer Market With New Imfinzi Safety Study

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confi...

TipRanks 6d
CSPC Receives US$30 Million Upfront Payment from AstraZeneca for siRNA Collaboration

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.